BACKGROUND: Hepatitis occurs frequently in patients with end-stage renal disease. In 1997, 0.7% of patients receiving a renal transplant were positive for hepatitis C antibodies. Concern has been raised as to whether these patients are at an increased mortality risk after renal transplantation compared with patients who are hepatitis C antibody negative. To help answer this question, we analyzed data from the United States Renal Data System from October of 1988 through June of 1998. METHODS: Primary study endpoints were patient death and death censored graft loss. Secondary study endpoints included cardiovascular, infectious, malignant, and infection-related death. Kaplan-Meier survival estimates as well as Cox proportional hazard models were used to evaluate the impact of hepatitis C antibody status on the study endpoints. RESULTS: A total of 73,707 patients were analyzed. Patient survival by Kaplan-Meier analysis was higher in hepatitis C-positive patients, whereas death censored graft survival trended lower in the very long term. By the Cox model, hepatitis C-positive adjusted patient survival is slightly superior to that of hepatitis C-negative patients. CONCLUSIONS: Renal transplant recipients who are hepatitis C antibody positive do not have an increased risk of death after transplantation compared with hepatitis C-negative recipients. The current policy of transplanting hepatitis C-positive patients without active liver disease seems to incur no excess mortality risk.
BACKGROUND:Hepatitis occurs frequently in patients with end-stage renal disease. In 1997, 0.7% of patients receiving a renal transplant were positive for hepatitis C antibodies. Concern has been raised as to whether these patients are at an increased mortality risk after renal transplantation compared with patients who are hepatitis C antibody negative. To help answer this question, we analyzed data from the United States Renal Data System from October of 1988 through June of 1998. METHODS: Primary study endpoints were patientdeath and death censored graft loss. Secondary study endpoints included cardiovascular, infectious, malignant, and infection-related death. Kaplan-Meier survival estimates as well as Cox proportional hazard models were used to evaluate the impact of hepatitis C antibody status on the study endpoints. RESULTS: A total of 73,707 patients were analyzed. Patient survival by Kaplan-Meier analysis was higher in hepatitis C-positivepatients, whereas death censored graft survival trended lower in the very long term. By the Cox model, hepatitis C-positive adjusted patient survival is slightly superior to that of hepatitis C-negative patients. CONCLUSIONS: Renal transplant recipients who are hepatitis C antibody positive do not have an increased risk of death after transplantation compared with hepatitis C-negative recipients. The current policy of transplanting hepatitis C-positivepatients without active liver disease seems to incur no excess mortality risk.
Authors: James R Cassuto; Matthew H Levine; Peter P Reese; Roy D Bloom; Simin Goral; Ali Naji; Peter L Abt Journal: Clin J Am Soc Nephrol Date: 2011-11-10 Impact factor: 8.237
Authors: Clarence E Foster; Benjamin Philosophe; Eugene J Schweitzer; John O Colonna; Alan C Farney; Bruce Jarrell; Leslie Anderson; Stephen T Bartlett Journal: Ann Surg Date: 2002-12 Impact factor: 12.969
Authors: Nae-Yun Heo; Ajitha Mannalithara; Donghee Kim; Prowpanga Udompap; Jane C Tan; W Ray Kim Journal: Transplantation Date: 2018-03 Impact factor: 4.939
Authors: J Hassanzadeh; A A Hashiani; A Rajaeefard; H Salahi; E Khedmati; F Kakaei; S Nikeghbalian; A Malek-Hossein Journal: Indian J Nephrol Date: 2010-10
Authors: A Almasi-Hashiani; A R Rajaeefard; J Hassanzade; H Salahi; S Nikeghbalian; P Janghorban; S A Malek-Hosseini Journal: Iran Red Crescent Med J Date: 2011-06-01 Impact factor: 0.611